<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627727</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000622</org_study_id>
    <nct_id>NCT04627727</nct_id>
  </id_info>
  <brief_title>Effect of a Low FODMAP Diet on SIBO</brief_title>
  <official_title>Effect of a Low FODMAP Diet on SIBO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bloating is the most common symptom associated with disorders of brain-gut interaction (i.e.,&#xD;
      functional bowel disorders) such as irritable bowel syndrome, a disorder characterized by&#xD;
      abdominal pain and altered bowel habits which affects up to 11% of world population. A common&#xD;
      cause of bloating is small intestinal bacterial overgrowth (SIBO), a condition defined by&#xD;
      excessive and/or abnormal type of bacteria in the small bowel. The potential role of SIBO for&#xD;
      irritable bowel syndrome (IBS) was initially proposed by Pimentel et al. Using lactulose&#xD;
      breath tests (LBTs), 78% of patients with IBS were also diagnosed with SIBO. After antibiotic&#xD;
      therapy, 48% of patients no longer met the Rome criteria for IBS. A recent systematic review&#xD;
      and meta-analysis concluded that the prevalence of SIBO is increased in IBS.&#xD;
&#xD;
      Despite the clinical efficacy of LFD in improving symptoms of IBS-D, its mechanism of action&#xD;
      is not clear. Recently, Zhou et al have shown FODMAPs induce colonic tight junction&#xD;
      dysfunction and visceral hypersensitivity in rat models, both of which are reversible when&#xD;
      rats were fed an LFD. They further showed that this effect of FODMAPs is mediated by&#xD;
      microbial dysbiosis and elevated fecal lipopolysaccharide level. However, studies evaluating&#xD;
      the effect of LFD on colonic permeability of humans are lacking. Studies have shown&#xD;
      significant differences in intra-individual luminal and mucosal microbiome of patients with&#xD;
      functional gastrointestinal disorders as well as an increase in Prevotella abundance in IBS&#xD;
      patients with SIBO as compared with IBS patients without SIBO. Thus, the exact effect of&#xD;
      FODMAP on intestinal permeability and mucosal microbiome in humans is not clear and needs&#xD;
      further evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">November 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SIBO diagnosis</measure>
    <time_frame>three weeks</time_frame>
    <description>presence or absence of SIBO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rome IV Functional Bloating diagnostic criteria</measure>
    <time_frame>3 weeks</time_frame>
    <description>Rome IV Functional Bloating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-SSS</measure>
    <time_frame>3 weeks</time_frame>
    <description>change in IBS-SSS from baseline to final</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum LPS level</measure>
    <time_frame>3 weeks</time_frame>
    <description>change in serum LPS concentration from baseline to final</description>
  </other_outcome>
  <other_outcome>
    <measure>serum zonulin level</measure>
    <time_frame>3 weeks</time_frame>
    <description>change in serum zonulin concentration from baseline to final</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>SIBO</condition>
  <arm_group>
    <arm_group_label>low FODMAP diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low FODMAP diet</intervention_name>
    <description>low FODMAP diet</description>
    <arm_group_label>low FODMAP diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-65 years at the time of screening&#xD;
&#xD;
          -  Meet Rome IV criteria for functional bloating&#xD;
&#xD;
          -  IBS-SSS score of at 176 (0-500)&#xD;
&#xD;
          -  SIBO positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals already on a LFD or other dietary restriction such as gluten free diet&#xD;
             within the past 6 months&#xD;
&#xD;
          -  individuals with peanut, soy, or seafood allergies or insulin-dependent diabetes&#xD;
&#xD;
          -  known history of celiac disease, inflammatory bowel disease or microscopic colitis&#xD;
&#xD;
          -  prior small bowel or colonic surgery or cholecystectomy&#xD;
&#xD;
          -  pregnant patients&#xD;
&#xD;
          -  antibiotics, excluding topical, in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Lembo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

